Profiling Biological Markers in Adults With Migraine
Studies chemical signals and microRNA linked to migraine in adults aged 18 to 55.
Plain-language title generated from the registry record
Registry title: Biological Profiles of Neuropeptides, Neurotrophins and miRNA in Migraine
Key facts
- Where
- Bodø, NorwaySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT07832032, who can take part
Where in Norway
- Departement of Neurology, NLSH HFBodø, NorwayNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nordlandssykehuset HF
- Trial code
- NCT07832032
- Record updated
- 10 November 2026
- Original description
There are still no reliable biomarkers for migraine; the diagnosis is based on symptomatology, and the pathogenesis remains largely a mystery. However, the past decade has seen a shift from a trial-and-error treatment strategy to a more biologically driven approach using CGRP-targeted drugs (gepants) and monoclonal antibodies (mAbs). This study aims to profile levels of perivascular and hypothalamic neuropeptides, as well as microRNA (miRNA) and neurotrophins, in individuals with migraine. The study builds on a previous pilot investigation (Neuropeptides during migraine attacks, REK 808581).Read full original descriptionShow less
Biological Profiling Subjects With Migraine
There are still no reliable biomarkers for migraine; the diagnosis is based on symptomatology, and the pathogenesis remains largely a mystery. However, the past decade has seen a shift from a trial-and-error treatment strategy to a more biologically driven approach using CGRP-targeted drugs (gepants) and monoclonal antibodies (mAbs). This study aims to profile levels of perivascular and hypothalamic neuropeptides, as well as microRNA (miRNA) and neurotrophins, in individuals with migraine. The study builds on a previous pilot investigation (Neuropeptides during migraine attacks, REK 808581).
Inclusion: Informed and written consent; Men and women, between 18 and 55 years of age; Master a Scandinavian language at level sufficient to fully understand the written and verbal study information; Migraine, with or without aura, fulfilling the International Classification of Headache Disorders (ICHD) III criteria for episodic migraine at time of inclusion. They must report at least 1 attack per month requiring the use of acute medication; Consent to fill out a headache diary for up to 6 months.
Exclusion: The subject is unable to differentiate migraine from other concomitant headaches; The subject having chronic migraine or other chronic pain conditions; The subject has severe psychiatric disorders (including depression), substance abuse, severe somatic disorders, and any medical condition that could alter tear and saliva production; Eye disorders that cause pain, require medication or affect tear production; Pregnancy; Smoking; Subjects using tricyclic antidepressant or CGRP antagonists; Contraindication for gepants.